Barclays Reaffirms Their Buy Rating on Cencora (COR)
TipRanks (Wed, 10-Jun 5:15 AM ET)
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
Business Wire (Wed, 27-May 6:55 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR
Globe Newswire (Tue, 26-May 5:43 PM ET)
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
Business Wire (Thu, 21-May 4:30 PM ET)
COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm
Globe Newswire (Mon, 18-May 2:53 PM ET)
Business Wire (Fri, 15-May 7:20 PM ET)
Business Wire (Mon, 11-May 12:00 PM ET)
Business Wire (Mon, 11-May 9:00 AM ET)
Business Wire (Fri, 8-May 5:26 PM ET)
Cencora Ups Guidance as Healthcare and International Growth Drive Q2 Results
Market Chameleon (Wed, 6-May 4:44 AM ET)
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of June 10, 2026, COR stock price climbed to $281.55 with 149,875 million shares trading.
COR has a beta of -0.07, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $54.77 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $78 billion in Revenue and $4.75 earnings per share. This fell short of revenue expectation by $-3 billion and exceeded earnings estimates by $.01.
The top ETF exchange traded funds that COR belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
COR has underperformed the market in the last year with a return of 0.0%, while the SPY ETF gained +23.8%. In the last 3 month period, COR fell short of the market, returning -22.0%, while SPY returned +8.6%. However, in the most recent 2 weeks COR has outperformed the stock market by returning +4.0%, while SPY returned -2.1%.
COR support price is $274.96 and resistance is $284.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR shares will trade within this expected range on the day.